843 related articles for article (PubMed ID: 6430638)
1. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel.
Gaspard UJ; Dubois M; Gillain D; Franchimont P; Duvivier J
Contraception; 1984 Apr; 29(4):305-18. PubMed ID: 6430638
[TBL] [Abstract][Full Text] [Related]
2. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel.
Gaspard UJ; Romus MA; Gillain D; Duvivier J; Demey-Ponsart E; Franchimont P
Contraception; 1983 Jun; 27(6):577-90. PubMed ID: 6225622
[TBL] [Abstract][Full Text] [Related]
3. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
London RS; Chapdelaine A; Upmalis D; Olson W; Smith J
Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
[TBL] [Abstract][Full Text] [Related]
4. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R
Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
[TBL] [Abstract][Full Text] [Related]
5. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives.
Aden U; Jung-Hoffmann C; Kuhl H
Contraception; 1998 Aug; 58(2):75-81. PubMed ID: 9773261
[TBL] [Abstract][Full Text] [Related]
6. Pituitary and ovarian function in women receiving hormonal contraception.
Cohen BL; Katz M
Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456
[TBL] [Abstract][Full Text] [Related]
7. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
[TBL] [Abstract][Full Text] [Related]
8. A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters: I. Effects upon sexual hormone levels.
Kuhl H; Gahn G; Romberg G; März W; Taubert HD
Contraception; 1985 Jun; 31(6):583-93. PubMed ID: 2931247
[TBL] [Abstract][Full Text] [Related]
9. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
Wiegratz I; Jung-Hoffmann C; Kuhl H
Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel.
Lemay A; Dewailly SD; Grenier R; Huard J
J Clin Endocrinol Metab; 1990 Jul; 71(1):8-14. PubMed ID: 2142494
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
Carlström K; Lunell NO; Zador G
Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
[TBL] [Abstract][Full Text] [Related]
12. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
Rossmanith WG; Steffens D; Schramm G
Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
[TBL] [Abstract][Full Text] [Related]
13. The mechanism of action of a new low-dosed combined oral contraceptive.
Dericks-Tan JS; Schneider K; Taubert HD
Arch Gynecol; 1980; 229(2):107-14. PubMed ID: 6768343
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effects of two triphasic formulations containing ethinyl estradiol and dl-norgestrel.
Smith RP; Sizto R
Contraception; 1983 Aug; 28(2):189-99. PubMed ID: 6641221
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting pituitary gonadotropin function in users of oral contraceptive steroids.
Scott JA; Brenner PF; Kletzky OA; Mishell DR
Am J Obstet Gynecol; 1978 Apr; 130(7):817-21. PubMed ID: 345817
[TBL] [Abstract][Full Text] [Related]
17. Ovarian activity suppression by two different low-dose triphasic oral contraceptives.
van der Does J; Exalto N; Dieben T; Bennink HC
Contraception; 1995 Dec; 52(6):357-61. PubMed ID: 8749599
[TBL] [Abstract][Full Text] [Related]
18. Serum gonadotropin and ovarian steroid levels in women during administration of a norethindrone-ethinylestradiol triphasic oral contraceptive.
Ling WY; Johnston DW; Lea RH; Bent AE; Scott JZ; Toews MR
Contraception; 1985 Oct; 32(4):367-75. PubMed ID: 3935373
[TBL] [Abstract][Full Text] [Related]
19. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
[TBL] [Abstract][Full Text] [Related]
20. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
Notelovitz M; Kitchens CS; Khan FY
Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
